Biotech Leads. Qualified. At Scale.

You are sending outreach to VP Business Development at a 60-person biotech that just posted a Phase I trial registration. Your clinical data management platform message talks about Phase III efficiencies and NDA submission timelines. The buyer reads the first sentence, knows immediately that you have not looked at their pipeline, and deletes it. Three months later that same company completes Phase I, closes a Series B, and starts evaluating Phase II vendors in earnest. You missed the window because your message confirmed you did not understand where they were in development - and in biotech, that first impression is very hard to recover from.

We map every target company against ClinicalTrials.gov data, SEC and EMA filings, press releases, and funding announcements before a single email sends. Every sequence is timed to the buyer's actual development stage, and the copy references it directly. A pre-clinical target gets different messaging than a Phase II target, and neither gets the message written for a company preparing for commercial launch.

Your sequence opens with 'I noticed Arcivus Therapeutics is advancing a novel KRAS inhibitor into the clinic' - which is technically true, but every other vendor who read the same press release opened with the same line. CSOs and VP BD at clinical-stage biotechs receive between 30 and 60 vendor emails per week. Most of them open with a pipeline reference that could be pulled from a five-minute Google search. The result is pattern-matched deletion before the second sentence. Worse, a scientist receiving lazy copy about their own programme draws a direct conclusion about the quality of your product. Credibility lost before the conversation starts.

We go deeper than the pipeline headline. We cross-reference job postings for clinical operations or biostatistics roles, which signal scaling infrastructure. We track ClinicalTrials.gov protocol amendments, which signal operational strain. We identify partnership and licensing announcements to find the angle that reveals genuine understanding of where the company is heading - angles that other vendors have not already used and that make the buyer think the message was written specifically for them.

Your BDR sends 400 emails in the first two weeks of January targeting Heads of Regulatory Affairs at mid-size specialty pharma companies. Open rates look reasonable. But January is when regulatory teams are locked into annual submission calendars, preparing for PDUFA date responses, managing Type B meeting cycles with FDA, and finalising post-approval commitment reports. They are not evaluating new vendors. The same buyers become significantly more receptive from May through July when submission sprints have cleared and they are actively planning tooling and resourcing for the next development phase. Without understanding the regulatory calendar, you burn budget on outreach that lands at exactly the wrong moment and generates no signal worth learning from.

We map outreach timing to the pharmaceutical regulatory calendar and each company's known submission history, sourced from FDA's public PDUFA calendar and EMA's opinion schedule. We stagger volume around major PDUFA date clusters and FDA advisory committee cycles, and we prioritise accounts that have just cleared a major submission - the window where buyers are planning forward, not heads-down executing. Timing is as important as copy in this market.

You hired a specialist life sciences BDR at USD 75,000 base plus commission. You waited five months for ramp, during which they learned your product while writing sequences that were technically accurate but never converted because domain knowledge and outbound copywriting are different skills. After ten months they left for a VP of Sales role at a clinical-stage company. Everything they built - the contact lists, the qualification notes, the sequence logic, the rapport with warm prospects mid-cycle - left with them. Rebuilding costs another six months, another hiring cycle, and another ramp period. Meanwhile your pipeline is empty and your leadership team is asking why outbound is not working.

Our programme runs independently of any individual. Every contact list, sequence variant, qualification note, and performance data point lives in shared infrastructure that your team can access at any time. If a campaign manager changes, the next one picks up the same playbook on day one with full context. You get weekly written reporting showing exactly what is running, what changed, and what the data says about why.